GSK is funding public health organizations working to address US adult immunization gaps and increase community vaccine education, outreach and access These grants are part of GSK’s COiMMUNITY ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of oral antibiotics for the condition in nearly 30 years. Blujepa, also ...

Shortly after President Donald Trump won his second presidential election in the U.S. last fall, British drugmaker GSK came to federal prosecutors in New York, bearing intel from employees ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price target of £22.90. The company’s shares opened ...

In an interview with Bloomberg, GSK (GSK) CEO Emma Walmsley said the company has been anticipating tariffs on the industry and is “confident” the company can navigate through it, Ashleigh ...

LONDON, March 25 (Reuters) - GSK (GSK.L), opens new tab said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its best-selling shingles ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other most undervalued biotech stocks to invest in. On February 21, Jared Holz, Mizuho Securities ...

Learn More. Just over a year ago, I ran the rule over GSK (LSE: GSK) shares. They looked very cheap and were offering a growing dividend. However, I chose instead to invest in FTSE 100 ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya. The shot protects ...